Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 200Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 28Melanoma 26Adenocarcinoma of Lung 24Astrocytoma 21Stomach Neoplasms 20Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Esophageal Neoplasms 15Adenocarcinoma 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

Leucovorin 3Everolimus 3temsirolimus 2Trastuzumab 2Temozolomide 2Sirolimus 2Oxaliplatin 2Octreotide 2Melphalan 2Irinotecan 2Fluorouracil 2Capecitabine 2vatalanib 1tipifarnib 1regorafenib 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1cixutumumab 1batifiban 1Vinorelbine 1Thalidomide 1Taxes 1Streptozocin 1Sorafenib 1Paclitaxel 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Islet Cell × Bevacizumab × Clear all
NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Stanford University

Phase 2 Completed
20 enrolled 15 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡